Preliminary report: Measurement of apixaban and rivaroxaban in plasma from bleeding patients

Kathrine Overgaard Foss Jensen, Svend Høime Hansen, Jens Peter Gøtze, Amalie Jesting, Jakob Stensballe, Henrik Hansen

    Research output: Contribution to journalJournal articleResearchpeer-review

    Abstract

    Objectives
    The direct oral anticoagulants (DOACs), apixaban and rivaroxaban, are used for anticoagulation treatment. Although biochemical monitoring is not required, severe bleedings caused by DOAC have been reported. We therefore evaluated the chromogenic assay Biophen DiXaI® (Biophen) using plasma from non-bleeding patients in treatment with DOAC and on spiked plasma from patients with ongoing bleeding.
    Methods
    The Biophen method was compared with an in-house reference method; liquid chromatography-tandem mass spectrometry (LC-MS/MS) using plasma spiked with the compounds ranging from 20 to 1500 μg/L. Furthermore, the methods were compared using plasma from non-bleeding patients in treatment with DOAC (n = 106). In addition, plasma was collected from patients not treated with DOAC, but with ongoing bleeding and tested in spiking experiments (n = 14).
    Results
    Analysis of plasma from 106 patients receiving rivaroxaban (n = 91) or apixaban (n = 15) showed agreement and correlation between the methods. Measurement in spiked plasma from patients with active bleeding, however, revealed a 26% overestimation by the assay.
    Conclusions
    Our findings show that Biophen is suitable for measuring apixaban and rivaroxaban concentrations in plasma. However, our results in patients with active bleeding show an overestimation of 26%. This should be taken into account when assessing possible intoxication with apixaban and rivaroxaban in patients presenting with bleeding.
    Original languageEnglish
    JournalEuropean Journal of Haematology
    Volume99
    Issue number5
    Pages (from-to)431–436
    Number of pages6
    ISSN0902-4441
    DOIs
    Publication statusPublished - 1 Oct 2017

    Cite this